Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced that Kevin Finney, chief executive officer, and Gudarz Davar, M.D., chief medical officer, will present a company overview at the Stifel 2023 Virtual CNS Days on Tuesday, March 28, 2023 at 3:30 p.m. ET.

A live webcast of the presentation can be accessed online here and a replay will be available for 90 days following the presentation.

About Autobahn Therapeutics

Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders. Leveraging its proprietary brain-targeting chemistry platform, Autobahn aims to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta agonist, being developed as a potential adjunctive treatment for people with MDD, including those who have had an inadequate response to their antidepressant. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005396/en/